Published in Cancer Gene Ther on January 25, 2013
The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment. Clin Cancer Res (2015) 1.52
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85
Designing Herpes Viruses as Oncolytics. Mol Ther Oncolytics (2015) 0.79
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother (2016) 0.79
Promising oncolytic agents for metastatic breast cancer treatment. Oncolytic Virother (2015) 0.76
Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. Oncolytic Virother (2013) 0.75
Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine. Mol Ther Oncolytics (2017) 0.75
Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther (2015) 0.75
Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes. Onco Targets Ther (2017) 0.75
TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (1996) 11.29
Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science (1990) 6.70
The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci U S A (1997) 6.08
Crosstalk in NF-κB signaling pathways. Nat Immunol (2011) 6.05
Cloning of herpes simplex virus type 1 sequences representing the whole genome. J Virol (1981) 5.66
The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci U S A (1992) 4.90
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med (1999) 4.40
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33
When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology (1996) 4.02
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol (2009) 3.80
Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol Ther (1998) 3.64
Herpes simplex virus type 1 ICP0 plays a critical role in the de novo synthesis of infectious virus following transfection of viral DNA. J Virol (1989) 3.63
Genetic evidence for two distinct transactivation functions of the herpes simplex virus alpha protein ICP27. J Virol (1990) 3.63
Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest (2001) 3.28
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 2.94
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res (1991) 2.70
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res (1989) 1.94
Herpes simplex type 1 induction of persistent NF-kappa B nuclear translocation increases the efficiency of virus replication. Virology (1998) 1.91
The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther (2002) 1.73
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67
Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem (1987) 1.64
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol (2010) 1.64
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res (2010) 1.63
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res (2007) 1.41
Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res (2001) 1.41
Activation of I kappa b kinase by herpes simplex virus type 1. A novel target for anti-herpetic therapy. J Biol Chem (2001) 1.35
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer (2009) 1.32
Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J (2004) 1.24
Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol (2001) 1.24
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst (2011) 1.19
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet (2001) 1.17
Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther (1999) 1.12
5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg (2005) 1.09
Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther (2012) 1.08
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res (2011) 1.06
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J (2000) 1.06
Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther (2010) 1.05
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest (2002) 1.03
Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg (1996) 1.02
Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther (2009) 1.01
Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res (2003) 0.99
Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res (2001) 0.98
Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther (2006) 0.98
HSV-1-inducible proteins bind to NF-kappa B-like sites in the HSV-1 genome. Virology (1992) 0.96
Proteolytic processing of nuclear factor kappa B by calpain in vitro. FEBS Lett (1996) 0.93
Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene (2010) 0.93
Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer. Gene Ther (2006) 0.93
Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells. Cancer Gene Ther (2006) 0.93
Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol (2007) 0.92
Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected Vero cells. J Gen Virol (1991) 0.92
Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res (2000) 0.92
Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol (2009) 0.90
Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Cancer (2004) 0.87
UL31 of herpes simplex virus 1 is necessary for optimal NF-kappaB activation and expression of viral gene products. J Virol (2011) 0.86
Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine. J Med Virol (1987) 0.84
Use of modified agarose gel electrophoresis to resolve protein-DNA complexes for electrophoretic mobility shift assay. Biotechniques (1998) 0.78
Decrease in deoxyribonucleotide triphosphate pools and induction of alkaline-labile sites in mouse bone marrow cells by multiple treatments with methotrexate. Mutat Res (1993) 0.78
Methotrexate potentiates anti-herpes simplex virus type 1 activity of E-5-(2-bromovinyl)-2'-deoxyuridine. Acta Virol (1995) 0.76
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med (1999) 4.40
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res (1991) 4.31
Molecular structure of a gene, VMA1, encoding the catalytic subunit of H(+)-translocating adenosine triphosphatase from vacuolar membranes of Saccharomyces cerevisiae. J Biol Chem (1990) 3.47
Molecular cloning and sequence determination of cDNAs for alpha subunits of the guanine nucleotide-binding proteins Gs, Gi, and Go from rat brain. Proc Natl Acad Sci U S A (1986) 2.83
A new NEDD8-ligating system for cullin-4A. Genes Dev (1998) 2.82
Xenopus M phase MAP kinase: isolation of its cDNA and activation by MPF. EMBO J (1991) 2.68
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol (1995) 2.62
Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer (2000) 2.59
Evolutionary origin of a calcium-dependent protease by fusion of genes for a thiol protease and a calcium-binding protein? Nature (1985) 2.52
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol (1998) 2.17
Identification of the gene loci that predispose to rheumatoid arthritis. Int Immunol (1998) 2.16
Surgical management of phyllodes tumors. Arch Surg (1999) 2.16
Tissue-specific expression of three distinct types of rabbit protein kinase C. Nature (1987) 2.14
A second type of rat phosphoinositide-specific phospholipase C containing a src-related sequence not essential for phosphoinositide-hydrolyzing activity. J Biol Chem (1989) 2.06
Hepatic failure in a case of multiple myeloma-associated amyloidosis (kappa-AL) J Gastroenterol (1995) 2.01
Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci U S A (1990) 1.94
Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg (1999) 1.92
Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol (1986) 1.87
Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg (1996) 1.77
Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys (2001) 1.67
Isolation of a yeast essential gene, COF1, that encodes a homologue of mammalian cofilin, a low-M(r) actin-binding and depolymerizing protein. Gene (1993) 1.64
Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem (1989) 1.63
Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care (1994) 1.62
Asaia bogorensis gen. nov., sp. nov., an unusual acetic acid bacterium in the alpha-Proteobacteria. Int J Syst Evol Microbiol (2000) 1.60
The carboxy-terminal region of mammalian HSP90 is required for its dimerization and function in vivo. Mol Cell Biol (1994) 1.54
Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol (2014) 1.53
Muscle-specific calpain, p94, is degraded by autolysis immediately after translation, resulting in disappearance from muscle. J Biol Chem (1993) 1.52
Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood (1999) 1.51
Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 alpha/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int Immunol (2001) 1.50
Ablation of liver tumors using percutaneous RF therapy. AJR Am J Roentgenol (1998) 1.48
Serological and microbiological findings on 3 farms with equine leptospiral abortions. Equine Vet J (1994) 1.48
Post-prandial serum hyaluronan concentration in patients with chronic liver disease. Intern Med (1998) 1.46
Cerebral vascular resistance assessed by transcranial color Doppler ultrasonography in patients with chronic liver diseases. J Gastroenterol Hepatol (2001) 1.45
Genomewide-linkage and haplotype-association studies map intracranial aneurysm to chromosome 7q11. Am J Hum Genet (2001) 1.43
Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem (1990) 1.43
Ebastine inhibits T cell migration, production of Th2-type cytokines and proinflammatory cytokines. Clin Exp Allergy (2003) 1.42
Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J (2000) 1.41
Hepatocellular carcinoma with intra-atrial tumor growth. A clinicopathologic study of 18 autopsy cases. Arch Pathol Lab Med (1984) 1.40
Anomalously hindered E2 strength B(E2;2+(1)-->0+) in 16C. Phys Rev Lett (2004) 1.39
Molecular cloning of cytidine monophospho-N-acetylneuraminic acid hydroxylase. Regulation of species- and tissue-specific expression of N-glycolylneuraminic acid. J Biol Chem (1995) 1.39
Characterization of three thermophilic strains of Methanothrix ("Methanosaeta") thermophila sp. nov. and rejection of Methanothrix ("Methanosaeta") thermoacetophila. Int J Syst Bacteriol (1992) 1.38
Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab (1999) 1.35
Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer (2007) 1.35
Molecular cloning and sequencing of cDNA for rat cathepsin H. Homology in pro-peptide regions of cysteine proteinases. FEBS Lett (1987) 1.34
Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology (1999) 1.34
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
A fourth type of rabbit protein kinase C. Biochemistry (1988) 1.32
The primary structure of rat brain (cytoplasmic) dynein heavy chain, a cytoplasmic motor enzyme. Proc Natl Acad Sci U S A (1993) 1.30
Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology (1997) 1.30
Calcium-activated neutral protease and its endogenous inhibitor. Activation at the cell membrane and biological function. FEBS Lett (1987) 1.29
Molecular cloning of a novel brain-type Na(+)-dependent inorganic phosphate cotransporter. J Neurochem (2000) 1.29
Attitudes and opinions toward surgical research. A survey of surgical residents and their chairpersons. Ann Surg (1996) 1.28
Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res (1999) 1.27
Minimal-access surgery for staging of malignant melanoma. Arch Surg (1995) 1.27
Molecular cloning of a ubiquitously distributed microtubule-associated protein with Mr 190,000. J Biol Chem (1990) 1.27
Complete nucleotide sequence of the structural gene for alkaline proteinase from Pseudomonas aeruginosa IFO 3455. Infect Immun (1990) 1.24
Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol (1991) 1.23
A critical role for the proteasome activator PA28 in the Hsp90-dependent protein refolding. J Biol Chem (2000) 1.23
Microtubule-binding domain of tau proteins. J Biol Chem (1988) 1.23
TGF-beta 1 reciprocally controls chemotaxis of human peripheral blood monocyte-derived dendritic cells via chemokine receptors. J Immunol (2000) 1.21
Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17.1A chlorin(e6) immunoconjugate. Cancer Res (2000) 1.20
Clinical significance of serum hyaluronan in patients with chronic viral liver disease. J Gastroenterol Hepatol (1996) 1.19
Crystallization and properties of diamine oxidase from pig kidney. Biochem Biophys Res Commun (1967) 1.18
Cytomegalovirus infection of the central nervous system stem cells from mouse embryo: a model for developmental brain disorders induced by cytomegalovirus. Lab Invest (2000) 1.17
A new reaction for glycine biosynthesis. Biochem Biophys Res Commun (1966) 1.17
Purification of native p94, a muscle-specific calpain, and characterization of its autolysis. Biochem J (1998) 1.16
Two yeast genes encoding calmodulin-dependent protein kinases. Isolation, sequencing and bacterial expressions of CMK1 and CMK2. J Biol Chem (1991) 1.16
Glycin metabolism by rat liver mitochondria. I. Synthesis of two molecules of glycine from one molecule each of serine, bicarbonate and ammonia. J Biochem (1969) 1.15
Molecular cloning of the cDNA for the large subunit of the high-Ca2+-requiring form of human Ca2+-activated neutral protease. Biochemistry (1988) 1.15
A common amino acid sequence in 190-kDa microtubule-associated protein and tau for the promotion of microtubule assembly. J Biol Chem (1989) 1.15
In vitro DNA replication implicates O2-ethyldeoxythymidine in transversion mutagenesis by ethylating agents. Nucleic Acids Res (1992) 1.15
Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer (1999) 1.15
Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol (1996) 1.14
Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. Clin Chim Acta (1993) 1.14
Auditory-visual processing represented in the human superior temporal gyrus. Neuroscience (2007) 1.14
Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cell-carcinoma cell lines of the oral cavity. Int J Cancer (1993) 1.13
Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance. Oncogene (2006) 1.13
Participation of periodontal ligament cells with regeneration of alveolar bone. J Periodontol (2001) 1.13
Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome. Biochem Biophys Res Commun (1993) 1.13
Asaia siamensis sp. nov., an acetic acid bacterium in the alpha-proteobacteria. Int J Syst Evol Microbiol (2001) 1.13
Degradation of transcription factors, c-Jun and c-Fos, by calpain. FEBS Lett (1991) 1.13
The beta subunit of tryptophan synthase. Clarification of the roles of histidine 86, lysine 87, arginine 148, cysteine 170, and cysteine 230. J Biol Chem (1989) 1.11
Vasodilator effect of adrenomedullin and calcitonin gene-related peptide receptors in rat mesenteric vascular beds. Biochem Biophys Res Commun (1993) 1.11
Network-based gene expression analysis of intracranial aneurysm tissue reveals role of antigen presenting cells. Neuroscience (2008) 1.11
Evidence for multiple activators for stress-activated protein kinase/c-Jun amino-terminal kinases. Existence of novel activators. J Biol Chem (1995) 1.11
Ikaros expression as a marker for lymphoid progenitors during zebrafish development. Dev Dyn (2001) 1.11
Embryolethality and teratogenicity of butyl benzyl phthalate in rats. J Appl Toxicol (1992) 1.10
Effects of gap junction blockers on human neocortical synchronization. Neurobiol Dis (2006) 1.10
Molecular cloning and functional analysis of three subunits of yeast proteasome. Mol Cell Biol (1991) 1.10
Quantitative analysis of gene expressions related to inflammation in canine spastic artery after subarachnoid hemorrhage. Stroke (2001) 1.10
Isolation and sequence analyses of cDNA clones for the large subunits of two isozymes of rabbit calcium-dependent protease. J Biol Chem (1986) 1.09
Enzymatic properties of a novel phorbol ester receptor/protein kinase, nPKC. J Biochem (1989) 1.09
Identification of 11 novel mutations in 49 Korean patients with mucopolysaccharidosis type II. Clin Genet (2011) 1.09
Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology (1995) 1.08
Chemokines induce eosinophil degranulation through CCR-3. J Allergy Clin Immunol (2000) 1.08
Scratching behavior in various strains of mice. Skin Pharmacol Appl Skin Physiol (2001) 1.08
Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J Gastroenterol Hepatol (1999) 1.07